MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA's rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio.

The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.

Incyte (NASDAQ: INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company's pipeline has changed substantially over the past year, citing proof-of-concept data for its CALR antibody 989 in myelofibrosis and

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.